{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:59:50Z","timestamp":1793710790839,"version":"4.6.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.diabres.2023.110908","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T05:07:25Z","timestamp":1696482445000},"page":"110908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial"],"prefix":"10.1016","volume":"204","author":[{"given":"Hiddo J.L.","family":"Heerspink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-9023","authenticated-orcid":false,"given":"Andreas L.","family":"Birkenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8345-3288","authenticated-orcid":false,"given":"Helen M.","family":"Colhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Henrik","family":"Groop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Pratley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia E.","family":"Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-8110","authenticated-orcid":false,"given":"Jay S.","family":"Skyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-0103","authenticated-orcid":false,"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lawatscheck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Edfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus F.","family":"Scheerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3425-7528","authenticated-orcid":false,"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet B.","family":"McGill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2023.110908_b0005","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S2213-8587(17)30362-5","article-title":"Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank","volume":"6","author":"Thomas","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2023.110908_b0010","unstructured":"IDF Diabetes Atlas. Type 1 diabetes estimates in children and adults. 2022. https:\/\/diabetesatlas.org\/atlas\/t1d-index-2022\/ [Accessed 5 July 2023]."},{"key":"10.1016\/j.diabres.2023.110908_b0015","article-title":"CKD prevalence and risk are higher in adults with type 2 vs. type 1 diabetes-an assessment of 1.5 million patients recently evaluated in U.S. clinical practices","volume":"67:544\u2013P","author":"Cressman","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2023.110908_b0020","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1113\/jphysiol.2014.272328","article-title":"Diabetic kidney disease: from physiology to therapeutics","volume":"592","author":"Mora-Fern\u00e1ndez","year":"2014","journal-title":"J Physiol"},{"key":"10.1016\/j.diabres.2023.110908_b0025","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2337\/dc17-1118","article-title":"Cumulative kidney complication risk by 50 years of type 1 diabetes: The effects of sex, age, and calendar year at onset","volume":"41","author":"Costacou","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110908_b0030","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789\u2013858. 10.1016\/S0140-6736(18)32279-7."},{"key":"10.1016\/j.diabres.2023.110908_b0035","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S2213-8587(22)00099-7","article-title":"Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0\u201314 years: a population-based retrospective cohort study","volume":"10","author":"Jansson Sigfrids","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.diabres.2023.110908_b0040","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S2213-8587(23)00168-7","article-title":"People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action","volume":"11","author":"Heerspink","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2023.110908_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - new perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol Res"},{"issue":"6","key":"10.1016\/j.diabres.2023.110908_b0050","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.diabres.2023.110908_b0055","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","article-title":"Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study","volume":"29","author":"Nielsen","year":"2012","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2023.110908_b0060","unstructured":"Food and Drug Administration. Aldactone (spironolactone): US prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/012151s075lbl.pdf [Accessed 6 July 2023]."},{"key":"10.1016\/j.diabres.2023.110908_b0065","unstructured":"EMC. Aldactone (spironolactone) summary of product characteristics. 2022. https:\/\/www.medicines.org.uk\/emc\/product\/1619\/smpc\/print#INDICATIONS [Accessed 6 July 2023]."},{"key":"10.1016\/j.diabres.2023.110908_b0070","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfad101","article-title":"The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis","author":"Whitlock","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.diabres.2023.110908_b0075","first-page":"23","article-title":"Nonsteroidal mineralocorticoid receptor antagonism by finerenone-translational aspects and clinical perspectives across multiple organ systems","author":"Kolkhof","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"23","key":"10.1016\/j.diabres.2023.110908_b0080","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.diabres.2023.110908_b0085","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabres.2023.110908_b0090","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.diabres.2023.110908_b0095","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2023.110908_b0100","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabres.2023.110908_b0105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s43441-022-00445-6","article-title":"Innovations in pediatric therapeutics development: principles for the use of bridging biomarkers in pediatric extrapolation","volume":"57","author":"Fleming","year":"2023","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"10.1016\/j.diabres.2023.110908_b0110","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","article-title":"A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"103","author":"Bakris","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabres.2023.110908_b0115","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2337\/dci17-0047","article-title":"Are all patients with type 1 diabetes destined for dialysis if they live long enough?","volume":"41","author":"Bakris","year":"2018","journal-title":"Probably not. Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110908_b0120","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MED.0000000000000074","article-title":"Early diabetic nephropathy in type 1 diabetes: new insights","volume":"21","author":"Bjornstad","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.diabres.2023.110908_b0125","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Diabetes Control Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110908_b0130","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S2213-8587(14)70155-X","article-title":"Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study","volume":"2","author":"DCCT\/EDIC Research Group","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.diabres.2023.110908_b0135","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00125-019-05052-z","article-title":"Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus","volume":"63","author":"Colombo","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2023.110908_b0140","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2337\/dc13-2113","article-title":"Kidney disease and related findings in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study","volume":"37","author":"de Boer","year":"2014","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2023.110908_b0145","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00125-018-4564-8","article-title":"Regression of albuminuria and its association with incident cardiovascular outcomes and mortality in type 1 diabetes: the FinnDiane Study","volume":"61","author":"Jansson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2023.110908_b0150","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archinternmed.2011.16","article-title":"Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications cohort","volume":"171","author":"de Boer","year":"2011","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.diabres.2023.110908_b0155","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.2215\/CJN.02870316","article-title":"Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT\/EDIC study","volume":"11","author":"de Boer","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.diabres.2023.110908_b0160","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2023.110908_b0165","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2023.110908_b0170","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2023.110908_b0175","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 Clinical practice guideline for diabetes management in chronic kidney disease. 2022. https:\/\/kdigo.org\/wp-content\/uploads\/2022\/03\/KDIGO-2022-Diabetes-Management-GL_Public-Review-draft_1Mar2022.pdf [Accessed 11 July 2023]."},{"key":"10.1016\/j.diabres.2023.110908_b0180","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR endpoint study (CONFIDENCE)","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272300671X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272300671X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:28:55Z","timestamp":1759174135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882272300671X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":36,"alternative-id":["S016882272300671X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2023.110908","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2023.110908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110908"}}